


In the Claims

Applicant submits a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by strikeouts.

Please re-write the claims as follows:

1.-8. (Cancelled)

9. (Currently Amended) ~~The method of claim 1 wherein the compound has the formula A~~ method for treating a medical disorder in a subject mediated by the alteration of substrate activity comprising
administering to the subject an effective amount of a compound having the formula



wherein each D₁ and D₂ is a hydroxyl group or a group which is capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH; wherein X is an amino acid; and wherein C is bonded to B in the L-configuration, said amount being sufficient to prevent chemokine alteration by inhibiting DPP-IV activity, and
wherein the medical disorder is selected from the group consisting of arteriosclerosis and insufficient blood clotting.

10. (Original) The method of claim 9 wherein the compound is Val-boroPro.

11. (Previously Presented) The method of claim 9 wherein the compound is cyclic X-boroPro.

12. (Currently Amended) The method of claim 1 9 wherein the substrate is selected from the group consisting of SDF-1, RANTES, MIP-1, MIP-3, GLP-2, G-CSF, EPO, IL-6, IL-11, IL-8, Substance P, fibronectin, and monomeric fibrin.

13. (Cancelled)

14. (Currently Amended) The method of claim 1 9 wherein the compound is given to the subject by oral administration.


15. (Currently Amended) The method of claim 1 9 wherein the compound is given to the subject by parenteral administration.

16. (Currently Amended) The method of claim 1 9 wherein the effective amount is in the range of 0.01 mg/kg per day to 100 mg/kg per day.


17.-23. (Cancelled)

24. (Currently Amended) A method for treating an intestinal disease ~~consisting essentially of~~ comprising


administering to a subject in need thereof an effective amount of a compound having the formula




~~where T is selected from a group of the formula:~~




where each D_1 and D_2 , independently, is a hydroxyl group or a group which is capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH;
a group of the formula:




where G is either H, F, or an alkyl group containing 1 to 20 carbon atoms and, optionally, heteroatoms selected from the group consisting of N, S and O;
a phosphonate group of the formula:




where each J, independently, is any number of C, H, O, S or N atoms in any combination;
a group of formula




a group of formula



where R is a substituted or unsubstituted alkyl or aryl group, or an alkyl keto ester;
or a group of formula




Y is group of formula:



and each $R_1, R_2, R_3, R_4, R_5, R_6, R_7$, and R_8 is H;

X is any number of C, H, O, S, or N atoms; and


m can vary from 0 to 20;



wherein each D_1 and D_2 is a hydroxyl group or a group which is capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH, X is an amino acid, and wherein C is bonded to B in the L-configuration, said amount being sufficient to prevent chemokine alteration by inhibiting DPP-IV activity, and wherein the intestinal disease is not a cancer, tumor or neoplasm.

25. (New) The method of claim 9 wherein the compound has a binding or dissociation constant to DPP-IV of at least 10^{-9} M.

26. (New) A method for treating an intestinal disease consisting of administering to a subject in need thereof an effective amount of a compound having the formula



wherein each D_1 and D_2 is a hydroxyl group or a group which is capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH, X is an amino acid, and

Serial No.: 09/744,658
Docket No.: I0248.70014US00

- 6 -

C is bonded to B in the L-configuration, said amount being sufficient to prevent chemokine alteration by inhibiting DPP-IV activity, and
a pharmaceutically acceptable carrier,
wherein the intestinal disease is not a cancer, tumor or neoplasm.